![]() ![]() participants or (914) 987-7676 for international participants, and referencing conference ID 5380517 or via a live audio webcast that will be available online at. The conference call can be accessed by dialing (833) 362-0207 for U.S. Adjusted EBITDA less Patient Equipment Capex of $132 million to $142 million up from $113 million to $120 millionĪpria will host a conference call to discuss second quarter 2021 results on Augat 5:00 p.m.Adjusted EBITDA of $221 million to $231 million up from $207 million to $216 million.Net revenue of $1.12 billion to $1.15 billion up from $1.12 billion to $1.14 billion.Adjusted EBITDA less Patient Equipment Capex of $35 million to $38 millionįor the full year 2021, Apria is increasing guidance and is now projecting the following financial results:. ![]() Adjusted EBITDA of $57 million to $61 million.Net revenue of $282 million to $290 million.Adjusted EBITDA less Patient Equipment Capex of $44.1 million, up 2.2% from $43.1 millionįor the third quarter of 2021, Apria is currently projecting the following financial results:.Adjusted EBITDA of $64.4 million, up 15.5% compared to $55.7 million.Net Income of $20.6 million, or $0.54 per diluted share, up 153.1% from $8.1 million.Net revenue of $286.3 million, up 6.4% compared to $268.9 million.The Apria team has done an excellent job managing the complexities of the recall, and our entire organization continues to execute at a high level to help deliver the highest quality of care and service to our patients which positions us well to drive future growth.”Ĭomparisons are to the three months ended June 30, 2020. The recall has created significant disruption in the industry, and when coupled with the component shortages being experienced by other manufacturers, the availability of equipment to support newly diagnosed sleep and ventilation patients may be limited. Starck continued, “As most of you are aware, in mid-June, Philips/Respironics issued a product recall for a large portion of their CPAPs, BiPaps and ventilators. We continue to have a robust active pipeline and we expect to see more strategic M&A opportunities throughout the remainder of the year.” This acquisition enhances our presence in some attractive markets in Virginia and strengthens our relationships with the local health care systems. “On July 30, we signed a definitive agreement to acquire Airway Breathing Co., a provider of respiratory care services, sleep equipment and supplies, and durable medical equipment. “We delivered another strong quarter as our second quarter 2021 financial results were ahead of our expectations on all three of our key metrics, achieving organic net revenue growth of over 6.0% as compared to the prior year quarter,” said Dan Starck, CEO of Apria. (the “Company” or “Apria”) (Nasdaq: APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the second quarter ended June 30, 2021.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |